- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: Deoxycytidine, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR,NSC 127716 中文名稱:地西他濱
Decitabine是DNA甲基轉(zhuǎn)移酶抑制劑,整合進入DNA、導(dǎo)致DNA低甲基化,并使DNA復(fù)制停滯在intra-S-phase。Decitabine被用于治療骨髓增生異常綜合征(MDS)。Decitabine可在多種癌細胞系中誘導(dǎo)細胞周期阻滯和凋亡。
Decitabine Chemical Structure
CAS: 2353-33-5
相關(guān)靶點 | TET DNMT1 DNMT3 | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | RG108 SGI-1027 Zebularine (NSC 309132) Gamma-Oryzanol Bobcat339 hydrochloride CM272 GSK3685032 β-thujaplicin | 點擊展開 |
相關(guān)化合物庫 | 激酶抑制劑庫 FDA藥物庫 天然產(chǎn)物庫 已知活性藥物庫-I 生物活性庫Ⅱ | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
MV4-11 | Apoptosis Assay | 2.5 μM | 48?h? | decreases the cell viability co-treated with Tf-NP-sc | 23493348 |
OCI-AML3 | Apoptosis Assay | 2.5 μM | 48?h? | decreases the cell viability co-treated with Tf-NP-sc | 23493348 |
Kasumi-1 | Apoptosis Assay | 0.5 μM | 48?h? | decreases the cell viability co-treated with Tf-NP-sc | 23493348 |
AGS? | Growth Inhibition Assay | 5/10/20/50 μM | 48?h? | induces G2/M phase arrest? | 23582784 |
A549 | Apoptosis Assay | 5/10/20/50 μM | 48?h? | inhibits the cell viability? | 23582784 |
AGS | Apoptosis Assay | 5/10/20/50 μM | 48?h? | inhibits the cell viability? | 23582784 |
BT?474 | Function Assay | 0.2/1 μM | 72 h | causes re-expression of claudin?1? | 23844228 |
HCC1569 | Function Assay | 0.2/1 μM | 72 h | causes re-expression of claudin?1? | 23844228 |
MDA?MB?453 | Function Assay | 0.2/1 μM | 72 h | causes re-expression of claudin?1? | 23844228 |
HL-60 | Growth Inhibition Assay | 1 μM | 48 h | increases G2-phase cell fraction | 24000324 |
U251 | Apoptosis Assay | 1/10/100 μM | 7 d | induces cell apoptosis in a dose-dependent manner | 24146874 |
QBC-939 | Apoptosis Assay | 1/10/100 μM | 7 d | induces cell apoptosis in a dose-dependent manner | 24146874 |
LS174T | Apoptosis Assay | 1/10/100 μM | 7 d | induces cell apoptosis in a dose-dependent manner | 24146874 |
HepG2 | Apoptosis Assay | 1/10/100 μM | 7 d | induces cell apoptosis in a dose-dependent manner | 24146874 |
LS174T | Function Assay | 0.5/1 μM | 24 h | lead to an increase of OCTN2 levels | 24146874 |
HepG2 | Function Assay | 0.5/1 μM | 24 h | up-regulated the relative OCTN2 mRNA and protein expression | 24146874 |
U937-A/E-9/14/18? | Apoptosis Assay | 0.01/0.1/1/10 μM | 48 h | induces cell apoptosis in a dose-dependent manner | 24300456 |
HCT-116 | Function Assay | 250/500nM | 48 h | do not induces delayed and sustained ROS increase | 24423613 |
DLD-1 | Function Assay | 250/500nM | 48 h | do not induces delayed and sustained ROS increase | 24423613 |
ML-1 | Function Assay | 250/500nM | 48 h | induces delayed and sustained ROS increase | 24423613 |
HL-60 | Function Assay | 250/500nM | 48 h | induces delayed and sustained ROS increase | 24423613 |
CEM | Function Assay | 250/500nM | 48 h | induces delayed and sustained ROS increase | 24423613 |
BV-173 | Function Assay | 250/500nM | 48 h | induces delayed and sustained ROS increase | 24423613 |
KG-1a | Apoptosis Assay | 0.25/0.5/0.75/1 μM | 48/72/96 h | induces cell apoptosis in both dose- and time- dependent manner | 24423613 |
HL-60 | Apoptosis Assay | 0.25/0.5/0.75/1 μM | 48/72/96 h | induces cell apoptosis in both dose- and time- dependent manner | 24423613 |
ML-1 | Apoptosis Assay | 0.25/0.5/0.75/1 μM | 48/72/96 h | induces cell apoptosis in both dose- and time- dependent manner | 24423613 |
BV-173 | Apoptosis Assay | 0.25/0.5/0.75/1 μM | 48/72/96 h | induces cell apoptosis in both dose- and time- dependent manner | 24423613 |
NB4 | Function Assay | 2.5/5/7.5/10 μM | 24 h | increasea the expression of precursor miR-125a | 24484870 |
NCI-H929? | Growth Inhibition Assay | 1/2 μM | 24/48/72 h | affects cell cycle progression negatively | 24833108 |
JJN3? | Growth Inhibition Assay | 0.5/1 μM | 24/48/72 h | affects cell cycle progression negatively | 24833108 |
OPM-2? | Growth Inhibition Assay | 1/2 μM | 24/48/72 h | affects cell cycle progression negatively | 24833108 |
RPMI-8226 | Growth Inhibition Assay | 1/2 μM | 24/48/72 h | affects cell cycle progression negatively | 24833108 |
NCI-H929? | Apoptosis Assay | 1/2 μM | 72/96/120 h | induces cell apoptosis | 24833108 |
JJN3? | Apoptosis Assay | 0.5/1 μM | 24/48 h | induces cell apoptosis | 24833108 |
OPM-2? | Apoptosis Assay | 1/2 μM | 72/96/120 h | induces cell apoptosis | 24833108 |
RPMI-8226 | Apoptosis Assay | 1/2 μM | 48/72/96 h | induces cell apoptosis | 24833108 |
LOVO | Apoptosis Assay | 10 μM | 48 h | enhances Gefitinib-induced apoptosis | 24874286 |
SW1116? | Apoptosis Assay | 10 μM | 48 h | enhances Gefitinib-induced apoptosis | 24874286 |
LOVO | Function Assay | 10 μM | 48 h | increases the effective at inhibiting AKT and mTOR signaling pathways combined with gefitinib | 24874286 |
SW1116? | Function Assay | 10 μM | 48 h | increases the effective at inhibiting AKT and mTOR signaling pathways combined with gefitinib | 24874286 |
LOVO | Growth Inhibition Assay | 0.5/1/2/5 μM | 48 h | enhances the Gefitinib induced cell inhibition | 24874286 |
SW1116? | Growth Inhibition Assay | 0.5/1/2/5 μM | 48 h | enhances the Gefitinib induced cell inhibition | 24874286 |
Eca109 | Function Assay | 0.5/1 μM | 24 h | decreases expression of NF-κB2 and MMP2 | 25123082 |
Eca109 | Growth Inhibition Assay | 0.5?μM | 24 h | induces G2/M arrest in the cell cycle | 25123082 |
Eca109 | Function Assay | 0.5?μM | 24 h | inhibits cell invasion | 25123082 |
Eca109 | Function Assay | 0.5?μM | 6/12/24 h | inhibits cell migration? | 25123082 |
Eca109 | Growth Inhibition Assay | 0.5/2.5/5 μM | 24/48/72 h | inhibits cell growth in both dose- and time- dependent manner | 25123082 |
Eca109 | Function Assay | 0.5?μM | 24 h | modulates the gene expression of MAGE-A members | 25123082 |
NK? | Cytotoxity Assay | 0.02-20 μM | 5 d | decreases the cytolytic activity of NK cells at intermediate concentrations resulting in a U-shaped dose–response curve | 23328088 |
NK? | Apoptosis Assay | 0.02-20 μM | 5 d | decrease NK cell proliferation and viability as the concentration increased | 23328088 |
NK? | Function Assay | 0.01-20 μM | 5 d | causes hypomethylation of NK cells in a dose–response | 23328088 |
MOLT4/DNR | Function Assay | 5 μM | 4 d | reduces ABCB1 mRNA expression | 23060570 |
Jurkat/DOX | Function Assay | 5 μM | 4 d | reduces ABCB1 mRNA expression | 23060570 |
MOLT4/DNR | Growth Inhibition Assay | 5 μM | 4 d | reduces the IC50?value for daunorubicin sensitivity | 23060570 |
Jurkat/DOX | Growth Inhibition Assay | 5 μM | 4 d | reduces the IC50?value for daunorubicin sensitivity | 23060570 |
ccRCC? | Apoptosis Assay | 0.01-10μM | 72 h | has minimal effect on cell proliferation | 22826467 |
TNBC? | Apoptosis Assay | 0.01-10μM | 72 h | has minimal effect on cell proliferation | 22826467 |
A498 | Apoptosis Assay | 0.01-10μM | 72 h | induces synergistic responses?with romidepsin | 22826467 |
KIJ265T | Apoptosis Assay | 0.01-10μM | 72 h | induces synergistic responses?with romidepsin | 22826467 |
MDA-231 | Apoptosis Assay | 0.01-10μM | 72 h | induces synergistic responses?with romidepsin | 22826467 |
BT-20 | Apoptosis Assay | 0.01-10μM | 72 h | induces synergistic responses?with romidepsin | 22826467 |
U937 | Growth Inhibition Assay | 5-20 μM | 24/48/72 h | induces a decrease in cell viability in a concentration- and time-dependent manner | 22767021 |
HL60 | Growth Inhibition Assay | 5-20 μM | 24/48/72 h | induces a decrease in cell viability in a concentration- and time-dependent manner | 22767021 |
U937 | Apoptosis Assay | 15 μM | 24/48/72 h | induces cell apoptosis | 22767021 |
HL60 | Apoptosis Assay | 15 μM | 24/48/72 h | induces cell apoptosis | 22767021 |
LS411N? | Apoptosis Assay | 0.5 μM | 72 h | increases Fas mRNA level | 22461695 |
MDA-MB-231 | Apoptosis Assay | 10 μM | 48 h | reduces cell viability in a dose-dependent manner | 21887697 |
MCF-7? | Apoptosis Assay | 10 μM | 48 h | reduces cell viability in a dose-dependent manner | 21887697 |
A375 | Growth Inhibition Assay | 0.5 μM | 1/5/8 d | inhibits proliferation and induces differentiation of melanoma cells | 21796622 |
SKMEL1 | Growth Inhibition Assay | 0.5 μM | 1/5/8 d | inhibits proliferation and induces differentiation of melanoma cells | 21796622 |
SKMEL3 | Growth Inhibition Assay | 0.5 μM | 1/5/8 d | inhibits proliferation and induces differentiation of melanoma cells | 21796622 |
SKMEL28 | Growth Inhibition Assay | 0.5 μM | 1/5/8 d | inhibits proliferation and induces differentiation of melanoma cells | 21796622 |
MeWo | Growth Inhibition Assay | 0.5 μM | 1/5/8 d | inhibits proliferation and induces differentiation of melanoma cells | 21796622 |
B16 | Growth Inhibition Assay | 0.5 μM | 1/5/8 d | inhibits proliferation and induces differentiation of melanoma cells | 21796622 |
U373-MAGI | Antiviral assay | 0.25 to 8 uM | 2 to 72 hrs | Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 0.25 to 8 uM after 2 to 72 hrs by qPCR method | 27117260 |
U373-MAGI | Antiviral assay | 0.25 to 8 uM | 2 to 72 hrs | Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 0.25 to 8 uM after 2 to 72 hrs by qPCR method | 27117260 |
CD4+?CD25??T? | Function Assay | 1/5 μM | reduceS global DNA methylation | 24476360 | |
HCT116 | Growth Inhibition Assay | 72 h | IC50=1.7±0.4 μM | 24172061 | |
SW48 | Growth Inhibition Assay | 72 h | IC50=15.2±6.2 μM | 24172061 | |
HT29 | Growth Inhibition Assay | 72 h | IC50=1400±179 μM | 24172061 | |
Ly 1 | Growth Inhibition Assay | 24 h | IC50=7.3 μM | 21772049 | |
Ly 7 | Growth Inhibition Assay | 24 h | IC50=10.7 μM | 21772049 | |
Su-DHL6 | Growth Inhibition Assay | 24 h | IC50>20 μM | 21772049 | |
Ly 10 | Growth Inhibition Assay | 24 h | IC50>20 μM | 21772049 | |
RIVA | Growth Inhibition Assay | 24 h | IC50>20 μM | 21772049 | |
Su-DHL2 | Growth Inhibition Assay | 24 h | IC50>20 μM | 21772049 | |
Ly 1 | Growth Inhibition Assay | 48 h | IC50=0.34 μM | 21772049 | |
Ly 7 | Growth Inhibition Assay | 48 h | IC50=0.025 μM | 21772049 | |
Su-DHL6 | Growth Inhibition Assay | 48 h | IC50>20 μM | 21772049 | |
Ly 10 | Growth Inhibition Assay | 48 h | IC50=1.8 μM | 21772049 | |
RIVA | Growth Inhibition Assay | 48 h | IC50>20 μM | 21772049 | |
Su-DHL2 | Growth Inhibition Assay | 48 h | IC50=17.4 μM | 21772049 | |
Ly 1 | Growth Inhibition Assay | 72 h | IC50=0.01 μM | 21772049 | |
Ly 7 | Growth Inhibition Assay | 72 h | IC50=0.018 μM | 21772049 | |
Su-DHL6 | Growth Inhibition Assay | 72 h | IC50=1.6 μM | 21772049 | |
Ly 10 | Growth Inhibition Assay | 72 h | IC50=1.2 μM | 21772049 | |
RIVA | Growth Inhibition Assay | 72 h | IC50>20 μM | 21772049 | |
Su-DHL2 | Growth Inhibition Assay | 72 h | IC50=11.2 μM | 21772049 | |
HeLa | Kinase Assay | Ki=14.4 ± 4.6 μM for hCNT3 | 24780098 | ||
HeLa | Kinase Assay | Ki=21.6 ± 3.0 μM for hCNT1 | 24780098 | ||
HeLa | Kinase Assay | Ki=5.6 ± 0.5 μM for hENT2 | 24780098 | ||
HeLa | Kinase Assay | Ki=1000–5000 μM for hENT1 | 24780098 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Decitabine是DNA甲基轉(zhuǎn)移酶抑制劑,整合進入DNA、導(dǎo)致DNA低甲基化,并使DNA復(fù)制停滯在intra-S-phase。Decitabine被用于治療骨髓增生異常綜合征(MDS)。Decitabine可在多種癌細胞系中誘導(dǎo)細胞周期阻滯和凋亡。 | |
---|---|---|
特性 | Decitabine 是DNA甲基化的有效抑制劑。 | |
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Decitabine 有效抑制DNA 合成,這種作用存在劑量依賴性,作用于HL-60和 KG1a 白血病細胞時,IC50分別為 100 ng/mL 和1 ng/mL。Decitabine 抑制細胞生長,這種作用存在劑量和時間依賴性,處理HL-60和KG1a白血病細胞72小時和96小時,IC50分別約為100 ng/mL 和 10 ng/mL。[1] 最新研究顯示Decitabine作用于間變性大細胞淋巴瘤(ALCL),具有抗增殖和促凋亡活性,且抑制KARPAS-299細胞中[3H]胸甘的攝取,EC50 為0.49 μM。[2] |
|||
---|---|---|---|---|
激酶實驗 | DNA合成檢測 | |||
通過測定放射性胸甘攝入到DNA的情況而測定DNA合成比率。HL-60 和KG1a 細胞懸浮在6孔(直徑為35 mm )盤中,孔中為含10%胎牛血清的2 mL RPMI 培養(yǎng)基中,然后與不同濃度相應(yīng)藥物溫育48小時 (藥物同時加入)。48小時時, 每孔加入0.5 μCi [3H] 胸甘(6.7 Ci/mmol),再溫育24小時。細胞置于GF/C玻璃纖維過濾器(直徑為2.4 cm)中,使用冷 0.9% NaCl, 5% 冷三氯乙酸和乙醇清洗。烘干含DNA的過濾器,置于EcoLite閃爍液(ICN)中,使用 Beckman LS 6000IC 閃爍計數(shù)器測量放射性。通過劑量-反應(yīng)曲線計算IC50值。 | ||||
細胞實驗 | 細胞系 | HL-60 和 KG1a | ||
濃度 | 0 到100 ng/mL | |||
孵育時間 | 96 小時 | |||
方法 | 生長抑制實驗中,指數(shù)生長期細胞接種在5 ml培養(yǎng)基中。向培養(yǎng)基中同時加入不同濃度Decitabine。在指定時間,使用模型 ZM Coulter 計數(shù)器對細胞進行計數(shù)。根據(jù)藥物處理的白血病細胞的生長曲線,測定IC50值。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 phospho-p38 / p38 / phospho-NFκB / NFκB p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN Survivin / Bcl-2 / p53 / c-Myc / DNMT1 | 28152502 | ||
Immunofluorescence | E-cadherin / MMP-9 DNMT1 | 28152502 | ||
Growth inhibition assay | Cell viability | 26384351 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | Decitabine 按2.5 mg/kg 劑量作用于ALK+ KARPAS-299小鼠移植瘤模型,促進凋亡,且降低腫瘤細胞增殖,也導(dǎo)致腫瘤抑制基因p16INK4A的去甲基化。 [2] |
|
---|---|---|
動物實驗 | Animal Models | KARPAS-299 人類細胞皮下接種到小鼠的左右兩側(cè)。 |
Dosages | ≤2.5 mg/kg | |
Administration | 腹腔注射 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT06291285 | Not yet recruiting | Healthy Volunteers |
Novo Nordisk A/S |
February 27 2024 | Phase 1 |
NCT05960773 | Recruiting | Mesothelioma|Malignant Mesothelioma (MM)|Early-stage Mesothelioma|Subclinical Mesothelioma|BRCA1-Associated Protein-1 (BAP1) Mutations|Early-stage BAP1-associated Malignancies |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
January 31 2024 | Phase 2 |
NCT05835011 | Terminated | Myelodysplastic Syndromes |
Astex Pharmaceuticals Inc. |
July 14 2023 | Phase 2 |
NCT05816356 | Recruiting | Healthy |
EpiDestiny Inc.|Worldwide Clinical Trials |
March 24 2023 | Phase 1 |
分子量 | 228.21 | 分子式 | C8H12N4O4 |
CAS號 | 2353-33-5 | SDF | Download Decitabine SDF |
Smiles | C1C(C(OC1N2C=NC(=NC2=O)N)CO)O | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 45 mg/mL ( (197.18 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : 22.5 mg/mL (98.59 mM) Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
Is S1200 a racemic mixture or a monomer?
回答:
S1200 is R form